Top Growth Companies With High Insider Ownership On KRX In August 2024

Over the last 7 days, the South Korean market has risen by 7.9%, although it has remained flat over the past 12 months. With earnings expected to grow by 28% per annum in the coming years, identifying growth companies with high insider ownership can be crucial for investors looking to capitalize on this potential upswing.

Top 10 Growth Companies With High Insider Ownership In South Korea

Name	Insider Ownership	Earnings Growth
People & Technology (KOSDAQ:A137400)	16.5%	35%
Fine M-TecLTD (KOSDAQ:A441270)	17.2%	36.4%
Bioneer (KOSDAQ:A064550)	17.5%	89.7%
Global Tax Free (KOSDAQ:A204620)	18.1%	90.6%
Seojin SystemLtd (KOSDAQ:A178320)	29.6%	58.7%
Park Systems (KOSDAQ:A140860)	33%	36.6%
Vuno (KOSDAQ:A338220)	19.5%	105%
HANA Micron (KOSDAQ:A067310)	20%	97.4%
UTI (KOSDAQ:A179900)	33.1%	122.7%
Techwing (KOSDAQ:A089030)	18.7%	77.8%

Click here to see the full list of 86 stocks from our Fast Growing KRX Companies With High Insider Ownership screener.

We'll examine a selection from our screener results.

ALTEOGEN (KOSDAQ:A196170)

Simply Wall St Growth Rating: ★★★★★★

Overview: ALTEOGEN Inc., a bio company with a market cap of ₩16.10 trillion, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars.

Operations: The company's revenue segment primarily comprises ₩121.09 billion from biotechnology.

Insider Ownership: 26.6%

Revenue Growth Forecast: 48.7% p.a.

Alteogen, a South Korean growth company with high insider ownership, recently received approval from Korea's MFDS for its new drug Tergase®, which boasts over 99% purity and lower immunogenicity compared to existing products. The company's earnings are forecast to grow significantly at 72.95% per year, and revenue is expected to increase by 48.7% annually. Despite recent shareholder dilution and share price volatility, Alteogen's strong profit growth prospects and high return on equity forecast (45.2%) highlight its potential as a promising investment in the biotech sector.

• Navigate through the intricacies of ALTEOGEN with our comprehensive analyst estimates report here.
• The valuation report we've compiled suggests that ALTEOGEN's current price could be inflated.

CLASSYS (KOSDAQ:A214150)

Simply Wall St Growth Rating: ★★★★★☆

Overview: CLASSYS Inc. is a global provider of medical aesthetics devices with a market cap of ₩3.17 billion.

Operations: CLASSYS Inc. generates revenue primarily from its Surgical & Medical Equipment segment, which amounted to ₩191.53 million.

Insider Ownership: 10.1%

Revenue Growth Forecast: 21.2% p.a.

CLASSYS, a South Korean firm with high insider ownership, has demonstrated strong growth, with earnings increasing 25.9% annually over the past five years and forecasted to grow 22.84% per year. Revenue is expected to rise by 21.2% per year, outpacing the market average of 10%. Despite trading at 26.1% below estimated fair value and lacking recent insider trading activity, CLASSYS's robust profit growth and high return on equity forecast (28.4%) underscore its potential in the medical aesthetics sector.

• Get an in-depth perspective on CLASSYS' performance by reading our analyst estimates report here.
• In light of our recent valuation report, it seems possible that CLASSYS is trading beyond its estimated value.

PharmaResearch (KOSDAQ:A214450)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: PharmaResearch Co., Ltd., along with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea and has a market cap of ₩1.80 trillion.

Operations: The company generates revenue primarily from its pharmaceuticals segment, amounting to ₩280.29 billion.

Insider Ownership: 39%

Revenue Growth Forecast: 19.8% p.a.

PharmaResearch, a South Korean firm with high insider ownership, has shown impressive growth. Earnings grew by 55.4% over the past year and are forecasted to grow 20.74% annually, though slightly below the market average of 27.9%. Revenue is expected to increase by 19.8% per year, surpassing the market's 10%. Analysts agree on a potential stock price rise of 27.1%, and it's trading at a significant discount of 43.5% below estimated fair value despite recent volatility in its share price.

• Click here to discover the nuances of PharmaResearch with our detailed analytical future growth report.
• Insights from our recent valuation report point to the potential undervaluation of PharmaResearch shares in the market.

Next Steps

• Embark on your investment journey to our 86 Fast Growing KRX Companies With High Insider Ownership selection here.
• Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.
• Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.

Ready To Venture Into Other Investment Styles?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com